Your browser doesn't support javascript.
Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report.
Kaps, Leonard; Labenz, Christian; Grimm, Daniel; Schwarting, Andreas; Galle, Peter R; Schreiner, Oliver.
  • Kaps L; Department of Internal Medicine I University Medical Center of the Johannes Gutenberg-University Mainz Germany.
  • Labenz C; Institute of Translational Immunology University Medical Center of the Johannes Gutenberg-University Mainz Germany.
  • Grimm D; Department of Internal Medicine I University Medical Center of the Johannes Gutenberg-University Mainz Germany.
  • Schwarting A; Department of Internal Medicine I University Medical Center of the Johannes Gutenberg-University Mainz Germany.
  • Galle PR; Department of Internal Medicine I University Medical Center of the Johannes Gutenberg-University Mainz Germany.
  • Schreiner O; Department of Internal Medicine I University Medical Center of the Johannes Gutenberg-University Mainz Germany.
Clin Case Rep ; 8(12): 2990-2994, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-1335967
ABSTRACT
The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID-19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Language: English Journal: Clin Case Rep Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report Language: English Journal: Clin Case Rep Year: 2020 Document Type: Article